Abstract
BackgroundCancer and factor V Leiden mutation are both risk factors for venous thromboembolism (VTE). Cancer critically increases the thrombotic risk whereas Factor V Leiden is the most common pro-thrombotic mutation. The impact of the factor V Leiden on the risk of VTE in cancer patients remains uncertain.ObjectiveTo assess the impact of factor V Leiden mutation in cancer-associated thrombosis.MethodsThe EDITH hospital-based case-control study enrolled 182 patients with cancer and VTE as well as 182 control patients with cancer, matched for gender, age and cancer location, between 2000 and 2012, in the University Hospital of Brest. All cases and controls were genotyped for the factor V Leiden mutation and interviewed with a standardized questionnaire.ResultsTwenty one of 182 (11.5%) patients with cancer-associated thrombosis carried the factor V Leiden mutation and 4 of 182 (2.2%) controls with cancer but no venous thrombosis. In multivariate analysis including cancer stage and family history of VTE, cancer patients with factor V Leiden mutation had a seven-fold increased risk of venous thromboembolism (adjusted odds ratio [OR], 7.04; 95% CI, 2.01–24.63).ConclusionThe pro-thrombotic Factor V Leiden mutation was found to be an independent additional risk factor for venous thromboembolism in cancer patients and might therefore be considered in the individual thrombotic risk assessment.
Highlights
In multivariate analysis including cancer stage and family history of Venous thromboembolism (VTE), cancer patients with factor V Leiden mutation had a seven-fold increased risk of venous thromboembolism
Venous thromboembolism (VTE) is a frequent multifactorial disease defined as the occurrence of deep vein thrombosis (DVT) and/or pulmonary embolism (PE)
Between May 2000 and November 2011, among 2682 cases of VTE enrolled in the EDITH cohort study in Brest University Hospital, 1043 patients had an episode of unprovoked venous thrombosis, 493 patients had an active malignancy and 1146 were provoked by risk factors other than cancer
Summary
Cancer and factor V Leiden mutation are both risk factors for venous thromboembolism (VTE). Cancer critically increases the thrombotic risk whereas Factor V Leiden is the most common pro-thrombotic mutation. The impact of the factor V Leiden on the risk of VTE in cancer patients remains uncertain
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call